Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo Squares Off With Dr. Reddy’s In Lansoprazole Launch

This article was originally published in The Tan Sheet

Executive Summary

FDA denied Perrigo’s petition that had sought to block Dr. Reddy’s ANDA for generic Prevacid 24HR because it used bioequivalence data for the proton pump inhibitor’s Rx version. Competition between the firms is intensifying as Dr. Reddy’s expands its U.S. OTC presence.

Advertisement

Related Content

Perrigo Launch Investments Hold Income Back, As Firm Girds For 2013
Perrigo Launch Investments Hold Income Back, As Firm Girds For 2013
In Brief
Perrigo Feels Ill Effects Of Mild Cold Season, Excess OTC Capacity
Dr. Reddy’s Projects 50% Growth In U.S. OTC Business
Perrigo Seeks To Slow Rivals’ Private-Label Prevacid Launches
Prevacid 24HR Hits Shelves, Targets Rx-Users And Fed-Up Heartburn Sufferers

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS105756

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel